Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on SGLT 2 Inhibitor. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN117186035A details a high-yield synthesis for empagliflozin intermediates. Discover cost-effective manufacturing and reliable supply chain solutions for pharmaceutical production.
Patent CN103694230A reveals amino acid eutectic purification for Canagliflozin. Achieve <0.5% alpha-impurity with scalable, cost-effective pharmaceutical intermediate solutions.
Patent CN113735921B details a scalable synthesis for C-glycoside impurities, enhancing QC capabilities and reducing costs in API manufacturing for global supply chains.
Patent CN102046645B details a one-pot synthesis for high-purity spiroketal derivatives. This method ensures supply chain stability and cost reduction in API intermediate manufacturing.
Novel preparation method for SGLT-2 inhibitors via selective TMS deprotection. Reduces steps, eliminates column chromatography, ensures high purity for API manufacturing.
Patent CN114478454A reveals a convergent synthesis for SGLT2 inhibitors, offering significant cost reduction in API manufacturing and improved supply chain reliability.
Patent CN111269205B details a robust Pd-catalyzed method for C-aryl glycosides, offering high stereoselectivity and cost reduction in pharmaceutical intermediate manufacturing.
Discover the advanced purification method for Dapagliflozin in patent CN109705075B. Achieve high purity without protecting groups, ensuring cost reduction and supply reliability.
Novel patent CN108752184A offers eco-friendly SGLT2 intermediate synthesis. Reduces cost and waste. Reliable supplier for high-purity pharmaceutical intermediates.
Patent CN109988161A details a telescoped synthesis for Empagliflozin, offering significant cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.
Novel Pummerer reaction method for sulfur-containing aryl carbon glycosides. Mild conditions, high yield, suitable for API intermediate manufacturing.
Patent CN113801010A reveals a high-yield route for 5-bromo-2-chlorobenzoic acid, a key SGLT2 inhibitor intermediate, offering superior purity and supply chain stability.
Patent CN114933619A discloses potent thioglycoside analogs with nanomolar IC50. Streamlined Pd-catalyzed synthesis offers cost-effective pharma intermediate supply.
This novel cation exchange resin method reduces wastewater and improves purity for Empagliflozin manufacturing supply chain reliability and operational efficiency significantly.
Novel stable process for Empagliflozin manufacturing. Reduces impurities, ensures supply continuity, and offers cost-effective commercial scale-up for global pharmaceutical partners.
Patent CN113372315B details a robust method for synthesizing C-glucoside impurities, ensuring reliable supply chains and cost-effective API manufacturing for diabetes treatments.
Patent CN104945363B reveals a scalable synthesis for SGLT2 inhibitor intermediates, offering cost-effective alternatives to conventional dapagliflozin-based routes for pharmaceutical supply chains.
Advanced process for pyrazole-O-glycoside derivatives via catalytic hydrogenation and phase transfer glycosylation. Reliable supplier for high-purity pharmaceutical intermediates.
Patent CN110002989B reveals a high-selectivity synthesis for 5-bromo-2-chlorobenzoic acid, offering cost reduction and superior purity for SGLT-2 inhibitor manufacturing.
Novel dibromo-amino silica gel method achieves >99% selectivity and >99.8% purity for SGLT-2 inhibitors, significantly reducing waste and manufacturing costs.